{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:40:10Z","timestamp":1767876010845,"version":"3.49.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40121-023-00836-8","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T07:02:27Z","timestamp":1688972547000},"page":"2193-2219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-3841","authenticated-orcid":false,"given":"George","family":"Kassianos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-6019","authenticated-orcid":false,"given":"Osamah","family":"Barasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-363X","authenticated-orcid":false,"given":"Victoria","family":"Abbing-Karahagopian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-5034","authenticated-orcid":false,"given":"Mansour","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-6173","authenticated-orcid":false,"given":"Serdar","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-282X","authenticated-orcid":false,"given":"Angelika","family":"Banzhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7203","authenticated-orcid":false,"given":"Selim","family":"Badur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","volume":"18","author":"R Acevedo","year":"2019","unstructured":"Acevedo R, Bai X, Borrow R, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18:15\u201330. https:\/\/doi.org\/10.1080\/14760584.2019.1557520.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483\u201398. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.079.","journal-title":"J Infect"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37:2768\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.020.","journal-title":"Vaccine"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774\u201383. https:\/\/doi.org\/10.1016\/S1474-4422(12)70180-1.","journal-title":"Lancet Neurol"},{"issue":"Suppl 2","key":"836_CR5","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3-9. https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.062.","journal-title":"Vaccine"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, Muller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421\u201338. https:\/\/doi.org\/10.1007\/s40121-018-0213-2.","journal-title":"Infect Dis Ther"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/microorganisms9050900","volume":"9","author":"N Schiess","year":"2021","unstructured":"Schiess N, Groce NE, Dua T. The impact and burden of neurological sequelae following bacterial meningitis: a narrative review. Microorganisms. 2021;9:900. https:\/\/doi.org\/10.3390\/microorganisms9050900.","journal-title":"Microorganisms"},{"key":"836_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40121-021-00546-z","volume":"11","author":"J Shen","year":"2022","unstructured":"Shen J, Bouee S, Aris E, Emery C, Beck EC. Long-term mortality and state financial support in invasive meningococcal disease-real-world data analysis using the french national claims database (SNIIRAM). Infect Dis Ther. 2022;11:249\u201362. https:\/\/doi.org\/10.1007\/s40121-021-00546-z.","journal-title":"Infect Dis Ther"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","volume":"16","author":"R Borrow","year":"2017","unstructured":"Borrow R, Alarcon P, Carlos J, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313\u201328. https:\/\/doi.org\/10.1080\/14760584.2017.1258308.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:17. https:\/\/doi.org\/10.1186\/1478-7954-11-17.","journal-title":"Popul Health Metr"},{"key":"836_CR11","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","volume":"36","author":"SR Parikh","year":"2018","unstructured":"Parikh SR, Campbell H, Gray SJ, et al. Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010\u20132015. Vaccine. 2018;36:3876\u201381. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.038.","journal-title":"Vaccine"},{"key":"836_CR12","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1080\/21645515.2020.1849518","volume":"17","author":"MK Taha","year":"2021","unstructured":"Taha MK, Weil-Olivier C, Bouee S, et al. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021;17:1858\u201366. https:\/\/doi.org\/10.1080\/21645515.2020.1849518.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1.","journal-title":"MMWR Recomm Rep"},{"issue":"28","key":"836_CR14","doi-asserted-by":"publisher","first-page":"20522","DOI":"10.2807\/1560-7917.es2013.18.28.20522","volume":"18","author":"D Weiss","year":"2013","unstructured":"Weiss D, Varma JK. Control of recent community-based outbreaks of invasive meningococcal disease in men who have sex with men in Europe and the United States. Euro Surveill. 2013;18(28):20522. https:\/\/doi.org\/10.2807\/1560-7917.es2013.18.28.20522.","journal-title":"Euro Surveill"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/14760584.2022.2052048","volume":"21","author":"MK Taha","year":"2022","unstructured":"Taha MK, Martinon-Torres F, Kollges R, et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21:659\u201374. https:\/\/doi.org\/10.1080\/14760584.2022.2052048.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2022.03.032","volume":"119","author":"H Dubey","year":"2022","unstructured":"Dubey H, Oster P, Fazeli MS, et al. Risk factors for contracting invasive meningococcal disease and related mortality: a systematic literature review and meta-analysis. Int J Infect Dis. 2022;119:1\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2022.03.032.","journal-title":"Int J Infect Dis"},{"key":"836_CR17","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s40121-021-00499-3","volume":"10","author":"L Soumahoro","year":"2021","unstructured":"Soumahoro L, Abitbol V, Vicic N, Bekkat-Berkani R, Safadi MAP. Meningococcal disease outbreaks: a moving target and a case for routine preventative vaccination. Infect Dis Ther. 2021;10:1949\u201388. https:\/\/doi.org\/10.1007\/s40121-021-00499-3.","journal-title":"Infect Dis Ther"},{"key":"836_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40121-019-00262-9","volume":"8","author":"AR Muttalif","year":"2019","unstructured":"Muttalif AR, Presa JV, Haridy H, Gamil A, Serra LC, Cane A. Incidence and prevention of invasive meningococcal disease in global mass gathering events. Infect Dis Ther. 2019;8:569\u201379. https:\/\/doi.org\/10.1007\/s40121-019-00262-9.","journal-title":"Infect Dis Ther"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40121-022-00620-0","volume":"11","author":"S Badur","year":"2022","unstructured":"Badur S, Khalaf M, Ozturk S, et al. Meningococcal disease and immunization activities in Hajj and Umrah pilgrimage: a review. Infect Dis Ther. 2022;11:1343\u201369. https:\/\/doi.org\/10.1007\/s40121-022-00620-0.","journal-title":"Infect Dis Ther"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1093\/infdis\/jiac230","volume":"226","author":"KC Rudmann","year":"2022","unstructured":"Rudmann KC, Brown NE, Rubis AB, et al. Invasive meningococcal disease among people experiencing homelessness-United States, 2016\u20132019. J Infect Dis. 2022;226:S322\u20136. https:\/\/doi.org\/10.1093\/infdis\/jiac230.","journal-title":"J Infect Dis"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1080\/21645515.2020.1744979","volume":"16","author":"EC Dinleyici","year":"2020","unstructured":"Dinleyici EC, Borrow R. Meningococcal infections among refugees and immigrants: silent threats of past, present and future. Hum Vaccin Immunother. 2020;16:2781\u20136. https:\/\/doi.org\/10.1080\/21645515.2020.1744979.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jinf.2021.02.018","volume":"82","author":"EK Pilat","year":"2021","unstructured":"Pilat EK, Stuart JM, French CE. Tobacco smoking and meningococcal disease in adolescents and young adults: a systematic review and meta-analysis. J Infect. 2021;82:135\u201344. https:\/\/doi.org\/10.1016\/j.jinf.2021.02.018.","journal-title":"J Infect"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"010409","DOI":"10.7189\/jogh.09.010409","volume":"9","author":"ME Peterson","year":"2019","unstructured":"Peterson ME, Li Y, Bita A, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9:010409. https:\/\/doi.org\/10.7189\/jogh.09.010409.","journal-title":"J Glob Health"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"103571","DOI":"10.1016\/j.micpath.2019.103571","volume":"134","author":"A Purmohamad","year":"2019","unstructured":"Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571. https:\/\/doi.org\/10.1016\/j.micpath.2019.103571.","journal-title":"Microb Pathog"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3201\/eid2204.150653","volume":"22","author":"A Agnememel","year":"2016","unstructured":"Agnememel A, Hong E, Giorgini D, Nunez-Samudio V, Deghmane AE, Taha MK. Neisseria meningitidis Serogroup X in Sub-Saharan Africa. Emerg Infect Dis. 2016;22:698\u2013702. https:\/\/doi.org\/10.3201\/eid2204.150653.","journal-title":"Emerg Infect Dis"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/21645515.2018.1458175","volume":"14","author":"R Villena","year":"2018","unstructured":"Villena R, Safadi MAP, Valenzuela MT, Torres JP, Finn A, O\u2019Ryan M. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14:1042\u201357. https:\/\/doi.org\/10.1080\/21645515.2018.1458175.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","volume":"35","author":"R Whittaker","year":"2017","unstructured":"Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014. Vaccine. 2017;35:2034\u201341. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.007.","journal-title":"Vaccine"},{"key":"836_CR28","doi-asserted-by":"publisher","first-page":"2002075","DOI":"10.2807\/1560-7917.ES.2022.27.3.2002075","volume":"27","author":"C Nuttens","year":"2022","unstructured":"Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2022;27:2002075. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.3.2002075.","journal-title":"Euro Surveill"},{"key":"836_CR29","unstructured":"European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Stockholm. https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases. Accessed 26 Apr 2023."},{"key":"836_CR30","unstructured":"US Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. 2018. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2018.pdf. Accessed 26 Apr 2023."},{"key":"836_CR31","unstructured":"US Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. 2019. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2019.pdf. Accessed 26 Apr 2023."},{"key":"836_CR32","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/mSphere.00883-19","volume":"5","author":"RSW Tsang","year":"2020","unstructured":"Tsang RSW, Law DKS, De Paola R, et al. Culture-confirmed invasive meningococcal disease in Canada, 2010 to 2014: characterization of serogroup B Neisseria meningitidis strains and their predicted coverage by the 4CMenB vaccine. mSphere. 2020;5:e00883-e919. https:\/\/doi.org\/10.1128\/mSphere.00883-19.","journal-title":"mSphere."},{"key":"836_CR33","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2020.44.10","author":"MM Lahra","year":"2020","unstructured":"Lahra MM, Enriquez RP, Hogan TP, National Neisseria Network A. Australian Meningococcal Surveillance Programme annual report, 2018. Commun Dis Intell (2018). 2020. https:\/\/doi.org\/10.33321\/cdi.2020.44.10.","journal-title":"Commun Dis Intell (2018)"},{"key":"836_CR34","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2020.44.62","author":"MM Lahra","year":"2020","unstructured":"Lahra MM, Hogan TR, National Neisseria Network A. Australian Meningococcal Surveillance Programme annual report, 2019. Commun Dis Intell (2018). 2020. https:\/\/doi.org\/10.33321\/cdi.2020.44.62.","journal-title":"Commun Dis Intell (2018)."},{"key":"836_CR35","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2021.45.46","author":"MM Lahra","year":"2021","unstructured":"Lahra MM, George CRR, Shoushtari M, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2020. Commun Dis Intell (2018). 2021. https:\/\/doi.org\/10.33321\/cdi.2021.45.46.","journal-title":"Commun Dis Intell (2018)."},{"key":"836_CR36","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2022.46.46","author":"MM Lahra","year":"2022","unstructured":"Lahra MM, George CR, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2021. Commun Dis Intell (2018). 2022. https:\/\/doi.org\/10.33321\/cdi.2022.46.46.","journal-title":"Commun Dis Intell (2018)."},{"key":"836_CR37","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3201\/eid2704.191716","volume":"27","author":"Z Yang","year":"2021","unstructured":"Yang Z, Ren X, Davies H, et al. Genomic surveillance of a globally circulating distinct group W clonal complex 11 meningococcal variant, New Zealand, 2013\u20132018. Emerg Infect Dis. 2021;27:1087\u201397. https:\/\/doi.org\/10.3201\/eid2704.191716.","journal-title":"Emerg Infect Dis"},{"key":"836_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2017.04.007","volume":"75","author":"R Borrow","year":"2017","unstructured":"Borrow R, Caugant DA, Ceyhan M, et al. Meningococcal disease in the Middle East and Africa: findings and updates from the Global Meningococcal Initiative. J Infect. 2017;75:1\u201311. https:\/\/doi.org\/10.1016\/j.jinf.2017.04.007.","journal-title":"J Infect"},{"key":"836_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijid.2020.11.162","volume":"104","author":"MK Taha","year":"2021","unstructured":"Taha MK, Presa J, Serra L. A review of the epidemiology of invasive meningococcal disease and vaccination strategies in North Africa. Int J Infect Dis. 2021;104:189\u201397. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.162.","journal-title":"Int J Infect Dis"},{"key":"836_CR40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jinf.2018.01.007","volume":"76","author":"J Li","year":"2018","unstructured":"Li J, Shao Z, Liu G, et al. Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI). J Infect. 2018;76:429\u201337. https:\/\/doi.org\/10.1016\/j.jinf.2018.01.007.","journal-title":"J Infect"},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"e2071077","DOI":"10.1080\/21645515.2022.2071077","volume":"18","author":"J Xu","year":"2022","unstructured":"Xu J, Chen Y, Yue M, et al. Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010\u20132020: a systematic review and meta-analysis. Hum Vaccin Immunother. 2022;18:e2071077. https:\/\/doi.org\/10.1080\/21645515.2022.2071077.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR42","doi-asserted-by":"publisher","first-page":"e0088222","DOI":"10.1128\/spectrum.00882-22","volume":"10","author":"CS Chiou","year":"2022","unstructured":"Chiou CS, Liao YS, Chen BH, et al. Demographic features of invasive meningococcal disease in Taiwan, 1993 to 2020, and genetic characteristics of Neisseria meningitidis isolates, 2003 to 2020. Microbiol Spectr. 2022;10:e0088222. https:\/\/doi.org\/10.1128\/spectrum.00882-22.","journal-title":"Microbiol Spectr."},{"key":"836_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/14760584.2021.1899820","volume":"20","author":"MAP Safadi","year":"2021","unstructured":"Safadi MAP, Martinon-Torres F, Serra L, Burman C, Presa J. Translating meningococcal serogroup B vaccines for healthcare professionals. Expert Rev Vaccines. 2021;20:401\u201314. https:\/\/doi.org\/10.1080\/14760584.2021.1899820.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijid.2019.05.019","volume":"85","author":"PS Watson","year":"2019","unstructured":"Watson PS, Novy PL, Friedland LR. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease. Int J Infect Dis. 2019;85:22\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2019.05.019.","journal-title":"Int J Infect Dis"},{"key":"836_CR45","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","volume":"17","author":"JL Perez","year":"2018","unstructured":"Perez JL, Absalon J, Beeslaar J, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17:461\u201377. https:\/\/doi.org\/10.1080\/14760584.2018.1483726.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR46","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/microorganisms8101521","volume":"8","author":"M Pizza","year":"2020","unstructured":"Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8:1521. https:\/\/doi.org\/10.3390\/microorganisms8101521.","journal-title":"Microorganisms"},{"key":"836_CR47","unstructured":"European Medicines Agency Public Assessment Report (EPAR) for Bexsero. 2012. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bexsero. Accessed 5 Aug 2022."},{"key":"836_CR48","unstructured":"Electronic Medicines Compendium (UK). Bexsero meningococcal group B vaccine for injection in pre-filled syringe. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/5168. Accessed 5 Aug 2022."},{"key":"836_CR49","unstructured":"Therapeutic Goods Administration. Australian Product Information: BEXSERO\u00ae suspension for injection. Multicomponent meningococcal group B vaccine (recombinant, adsorbed). 2019. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_AU\/assets\/pdfs\/products\/bexsero\/bexsero_australian_product_information.pdf. Accessed 5 Aug 2022."},{"key":"836_CR50","unstructured":"European Medicines Agency Public Assessment Report (EPAR) for Trumenba. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trumenba. Accessed 5 Aug 2022."},{"key":"836_CR51","unstructured":"Electronic Medicines Compendium (UK). Trumenba. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/2670. Accessed 5 Aug 2022."},{"key":"836_CR52","unstructured":"Therapeutic Goods Administration. Australian Product Information: Trumenba\u00ae (Meningococcal group B vaccine) suspension for injection pre-filled syringe. 2019. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2017-PI-02674-1&d=20220818172310101. Accessed 5 Aug 2022."},{"key":"836_CR53","unstructured":"US Food & Drug Administration (FDA). BEXSERO\u00ae (Meningococcal Group B Vaccine). https:\/\/www.fda.gov\/media\/90996\/download. Accessed 5 Aug 2022."},{"key":"836_CR54","unstructured":"US Food & Drug Administration (FDA). Trumenba\u00ae (Meningococcal Group B Vaccine). https:\/\/www.fda.gov\/media\/89936\/download. Accessed 5 Aug 2022."},{"key":"836_CR55","unstructured":"GSK Canada. Bexsero. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed). 2022. https:\/\/ca.gsk.com\/media\/6328\/bexsero.pdf. Accessed 5 Aug 2022."},{"key":"836_CR56","unstructured":"Pfizer Canada. Trumenba. Meningococcal group B vaccine [Bivalent recombinant lipoprotein (rLP2086)]. 2019.https:\/\/www.pfizer.ca\/en\/our-products\/trumenba-meningococcal-group-b-vaccine. Accessed 5 Aug 2022."},{"key":"836_CR57","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1016\/j.vaccine.2022.04.101","volume":"40","author":"G Sulis","year":"2022","unstructured":"Sulis G, Horn M, Borrow R, Basta NE. A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine. 2022;40:3647\u201354. https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.101.","journal-title":"Vaccine"},{"key":"836_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martinon-Torres","year":"2022","unstructured":"Martinon-Torres F, Taha MK, Knuf M, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116:85\u201398. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health"},{"key":"836_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14760584.2022.2021881","volume":"21","author":"WY Sohn","year":"2022","unstructured":"Sohn WY, Tahrat H, Novy P, Bekkat-Berkani R. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Expert Rev Vaccines. 2022;21:325\u201335. https:\/\/doi.org\/10.1080\/14760584.2022.2021881.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jcpt.13083","volume":"45","author":"C Burman","year":"2020","unstructured":"Burman C, Alderfer J, Snow VT. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp. J Clin Pharm Ther. 2020;45:270\u201381. https:\/\/doi.org\/10.1111\/jcpt.13083.","journal-title":"J Clin Pharm Ther"},{"key":"836_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jinf.2021.04.031","volume":"83","author":"F Martinon-Torres","year":"2021","unstructured":"Martinon-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83:17\u201326. https:\/\/doi.org\/10.1016\/j.jinf.2021.04.031.","journal-title":"J Infect"},{"key":"836_CR62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382:318\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1900236.","journal-title":"N Engl J Med"},{"key":"836_CR63","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","volume":"73","author":"M McMillan","year":"2021","unstructured":"McMillan M, Chandrakumar A, Wang HLR, et al. Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and meta-analysis. Clin Infect Dis. 2021;73:e609\u201319. https:\/\/doi.org\/10.1093\/cid\/ciaa1733.","journal-title":"Clin Infect Dis"},{"key":"836_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/14760584.2022.2003708","volume":"21","author":"M McMillan","year":"2022","unstructured":"McMillan M, Marshall HS, Richmond P. 4CMenB vaccine and its role in preventing transmission and inducing herd immunity. Expert Rev Vaccines. 2022;21:103\u201314. https:\/\/doi.org\/10.1080\/14760584.2022.2003708.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR65","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/infdis\/jiab444","volume":"225","author":"M McMillan","year":"2022","unstructured":"McMillan M, Koehler AP, Lawrence A, et al. B part of it school leaver study: a repeat cross-sectional study to assess the impact of increasing coverage with meningococcal b (4CMenb) vaccine on carriage of Neisseria meningitidis. J Infect Dis. 2022;225:637\u201349. https:\/\/doi.org\/10.1093\/infdis\/jiab444.","journal-title":"J Infect Dis"},{"key":"836_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s12889-022-12933-3","volume":"22","author":"S Guedes","year":"2022","unstructured":"Guedes S, Bricout H, Langevin E, Tong S, Bertrand-Gerentes I. Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017\u2014a secondary database analysis. BMC Public Health. 2022;22:521. https:\/\/doi.org\/10.1186\/s12889-022-12933-3.","journal-title":"BMC Public Health"},{"issue":"Suppl 5","key":"836_CR67","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/1469-0691.12537","volume":"20","author":"P Bonanni","year":"2014","unstructured":"Bonanni P, Sacco C, Donato R, Capei R. Lifelong vaccination as a key disease-prevention strategy. Clin Microbiol Infect. 2014;20(Suppl 5):32\u20136. https:\/\/doi.org\/10.1111\/1469-0691.12537.","journal-title":"Clin Microbiol Infect"},{"key":"836_CR68","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.vaccine.2020.10.024","volume":"39","author":"P Bonanni","year":"2021","unstructured":"Bonanni P, Angelillo IF, Villani A, et al. Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let\u2019s avoid adding epidemics to the pandemic: appeal from the Board of the Vaccination Calendar for Life in Italy: maintain and increase coverage also by re-organizing vaccination services and reassuring the population. Vaccine. 2021;39:1187\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.024.","journal-title":"Vaccine"},{"key":"836_CR69","unstructured":"US Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. 2015. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2015.pdf. Accessed 26 Apr 2023."},{"key":"836_CR70","unstructured":"US Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. 2016. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report.pdf. Accessed 26 Apr 2023."},{"key":"836_CR71","unstructured":"US Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. 2017. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2017.pdf. Accessed 26 Apr 2023."},{"key":"836_CR72","unstructured":"US Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal Disease Surveillance Report. 2020. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2020.pdf. Accessed 26 Apr 2023."},{"key":"836_CR73","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","volume":"15","author":"R Booy","year":"2019","unstructured":"Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15:470\u201380. https:\/\/doi.org\/10.1080\/21645515.2018.1532248.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR74","doi-asserted-by":"publisher","first-page":"1800245","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245","volume":"24","author":"M Krone","year":"2019","unstructured":"Krone M, Gray S, Abad R, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24:1800245. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.14.1800245.","journal-title":"Euro Surveill"},{"key":"836_CR75","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","volume":"10","author":"V Masignani","year":"2019","unstructured":"Masignani V, Pizza M, Moxon ER. The development of a vaccine against meningococcus B using reverse vaccinology. Front Immunol. 2019;10:751. https:\/\/doi.org\/10.3389\/fimmu.2019.00751.","journal-title":"Front Immunol"},{"key":"836_CR76","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/14760584.2018.1547637","volume":"17","author":"R Rappuoli","year":"2018","unstructured":"Rappuoli R, Pizza M, Masignani V, Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17:1111\u201321. https:\/\/doi.org\/10.1080\/14760584.2018.1547637.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR77","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1016\/j.vaccine.2020.09.050","volume":"38","author":"A Biolchi","year":"2020","unstructured":"Biolchi A, De Angelis G, Moschioni M, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38:7542\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.050.","journal-title":"Vaccine"},{"key":"836_CR78","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40121-020-00370-x","volume":"10","author":"A Biolchi","year":"2021","unstructured":"Biolchi A, Tomei S, Brunelli B, et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2021;10:307\u201316. https:\/\/doi.org\/10.1007\/s40121-020-00370-x.","journal-title":"Infect Dis Ther"},{"key":"836_CR79","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1016\/j.vaccine.2018.05.081","volume":"36","author":"SL Harris","year":"2018","unstructured":"Harris SL, Tan C, Andrew L, et al. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine. 2018;36:6867\u201374. https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.081.","journal-title":"Vaccine"},{"key":"836_CR80","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40121-020-00319-0","volume":"9","author":"J Beeslaar","year":"2020","unstructured":"Beeslaar J, Absalon J, Anderson AS, et al. MenB-FHbp vaccine protects against diverse meningococcal strains in adolescents and young adults: post hoc analysis of two phase 3 studies. Infect Dis Ther. 2020;9:641\u201356. https:\/\/doi.org\/10.1007\/s40121-020-00319-0.","journal-title":"Infect Dis Ther"},{"key":"836_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","volume":"74","author":"M O'Ryan","year":"2014","unstructured":"O\u2019Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74:15\u201330. https:\/\/doi.org\/10.1007\/s40265-013-0155-7.","journal-title":"Drugs"},{"key":"836_CR82","doi-asserted-by":"publisher","first-page":"ftx025","DOI":"10.1093\/femspd\/ftx025","volume":"75","author":"J Findlow","year":"2017","unstructured":"Findlow J, Borrow R. Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility? Pathog Dis. 2017;75:ftx025. https:\/\/doi.org\/10.1093\/femspd\/ftx025.","journal-title":"Pathog Dis"},{"key":"836_CR83","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14760584.2022.2064850","volume":"21","author":"J Findlow","year":"2022","unstructured":"Findlow J, Borrow R, Stephens DS, et al. Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Rev Vaccines. 2022;21:753\u201369. https:\/\/doi.org\/10.1080\/14760584.2022.2064850.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR84","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jinf.2020.07.034","volume":"81","author":"R Borrow","year":"2020","unstructured":"Borrow R, Taha MK, Giuliani MM, Pizza M, Banzhoff A, Bekkat-Berkani R. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence. J Infect. 2020;81:862\u201372. https:\/\/doi.org\/10.1016\/j.jinf.2020.07.034.","journal-title":"J Infect"},{"key":"836_CR85","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","volume":"34","author":"C Brehony","year":"2016","unstructured":"Brehony C, Rodrigues CMC, Borrow R, et al. Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine. 2016;34:4690\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.015.","journal-title":"Vaccine"},{"key":"836_CR86","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","volume":"37","author":"A Muzzi","year":"2019","unstructured":"Muzzi A, Brozzi A, Serino L, et al. Genetic Meningococcal Antigen Typing System (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37:991\u20131000. https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.061.","journal-title":"Vaccine"},{"key":"836_CR87","doi-asserted-by":"publisher","first-page":"e00036","DOI":"10.1128\/mBio.00036-18","volume":"9","author":"LK McNeil","year":"2018","unstructured":"McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9:e00036\u201318. https:\/\/doi.org\/10.1128\/mBio.00036-18.","journal-title":"MBio"},{"key":"836_CR88","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.vaccine.2019.12.051","volume":"38","author":"JA Bettinger","year":"2020","unstructured":"Bettinger JA, Liberator P, Halperin SA, et al. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Vaccine. 2020;38:2026\u201333. https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.051.","journal-title":"Vaccine"},{"key":"836_CR89","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1514866","volume":"375","author":"NE Basta","year":"2016","unstructured":"Basta NE, Mahmoud AA, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375:220\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1514866.","journal-title":"N Engl J Med"},{"key":"836_CR90","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/cid\/cix519","volume":"65","author":"E Lujan","year":"2017","unstructured":"Lujan E, Winter K, Rovaris J, Liu Q, Granoff DM. Serum bactericidal antibody responses of students immunized with a meningococcal serogroup B vaccine in response to an outbreak on a university campus. Clin Infect Dis. 2017;65:1112\u20139. https:\/\/doi.org\/10.1093\/cid\/cix519.","journal-title":"Clin Infect Dis"},{"key":"836_CR91","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/INF.0000000000001399","volume":"36","author":"SL Harris","year":"2017","unstructured":"Harris SL, Donald RG, Hawkins JC, et al. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36:216\u201323. https:\/\/doi.org\/10.1097\/INF.0000000000001399.","journal-title":"Pediatr Infect Dis J"},{"key":"836_CR92","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.vaccine.2017.01.066","volume":"35","author":"MK Taha","year":"2017","unstructured":"Taha MK, Hawkins JC, Liberator P, et al. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017;35:1530\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.066.","journal-title":"Vaccine"},{"key":"836_CR93","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1097\/INF.0000000000002957","volume":"40","author":"A Biolchi","year":"2021","unstructured":"Biolchi A, Tomei S, Santini L, et al. Four-component meningococcal serogroup B vaccine induces antibodies with bactericidal activity against diverse outbreak strains in adolescents. Pediatr Infect Dis J. 2021;40:e66\u201371. https:\/\/doi.org\/10.1097\/INF.0000000000002957.","journal-title":"Pediatr Infect Dis J"},{"key":"836_CR94","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","volume":"69","author":"EA Semchenko","year":"2019","unstructured":"Semchenko EA, Tan A, Borrow R, Seib KL. The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae. Clin Infect Dis. 2019;69:1101\u201311. https:\/\/doi.org\/10.1093\/cid\/ciy1061.","journal-title":"Clin Infect Dis"},{"key":"836_CR95","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41541-021-00388-3","volume":"6","author":"Y Ruiz Garcia","year":"2021","unstructured":"Ruiz Garcia Y, Sohn WY, Seib KL, et al. Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. NPJ Vaccines. 2021;6:130. https:\/\/doi.org\/10.1038\/s41541-021-00388-3.","journal-title":"NPJ Vaccines"},{"key":"836_CR96","doi-asserted-by":"publisher","first-page":"2020043","DOI":"10.1080\/21645515.2021.2020043","volume":"18","author":"AE Deghmane","year":"2022","unstructured":"Deghmane AE, Taha MK. Product review on the IMD serogroup B vaccine Bexsero(R). Hum Vaccin Immunother. 2022;18:2020043. https:\/\/doi.org\/10.1080\/21645515.2021.2020043.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR97","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jinf.2017.12.005","volume":"76","author":"F Martinon-Torres","year":"2018","unstructured":"Martinon-Torres F, Carmona Martinez A, Simko R, et al. Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect. 2018;76:258\u201369. https:\/\/doi.org\/10.1016\/j.jinf.2017.12.005.","journal-title":"J Infect"},{"key":"836_CR98","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1080\/21645515.2019.1627159","volume":"15","author":"F Martinon-Torres","year":"2019","unstructured":"Martinon-Torres F, Nolan T, Toneatto D, Banzhoff A. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother. 2019;15:2940\u201351. https:\/\/doi.org\/10.1080\/21645515.2019.1627159.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR99","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S1473-3099(20)30600-9","volume":"21","author":"K Davis","year":"2021","unstructured":"Davis K, Valente Pinto M, Andrews NJ, et al. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2021;21:688\u201396. https:\/\/doi.org\/10.1016\/S1473-3099(20)30600-9.","journal-title":"Lancet Infect Dis"},{"key":"836_CR100","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","volume":"37","author":"T Nolan","year":"2019","unstructured":"Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37:1209\u201318. https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.059.","journal-title":"Vaccine"},{"key":"836_CR101","unstructured":"European Medicines Agency. Assessment report for paediatric studies submitted in accordance with article 46 of regulation (EC) No1901\/2006, as amended. Bexsero. Procedure no.: EMA\/H\/C\/002333 \/P46\/026. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/bexsero-h-c-2333-p46-026-epar-assessment-report_en.pdf. Accessed 5 Aug 2022."},{"key":"836_CR102","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.vaccine.2016.11.071","volume":"35","author":"RC Read","year":"2017","unstructured":"Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017;35:427\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.071.","journal-title":"Vaccine"},{"key":"836_CR103","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/hv.7.6.15482","volume":"7","author":"D Toneatto","year":"2011","unstructured":"Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7:646\u201353. https:\/\/doi.org\/10.4161\/hv.7.6.15482.","journal-title":"Hum Vaccin"},{"key":"836_CR104","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"A Kimura","year":"2011","unstructured":"Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483\u20136. https:\/\/doi.org\/10.1128\/CVI.00304-10.","journal-title":"Clin Vaccine Immunol"},{"key":"836_CR105","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1473-3099(16)30314-0","volume":"17","author":"HS Marshall","year":"2017","unstructured":"Marshall HS, Richmond PC, Beeslaar J, et al. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2017;17:58\u201367. https:\/\/doi.org\/10.1016\/S1473-3099(16)30314-0.","journal-title":"Lancet Infect Dis"},{"key":"836_CR106","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.vaccine.2018.11.073","volume":"37","author":"T Vesikari","year":"2019","unstructured":"Vesikari T, Ostergaard L, Beeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37:1710\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.073.","journal-title":"Vaccine"},{"key":"836_CR107","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI). Australian immunisation handbook 2020. https:\/\/www.health.gov.au\/health-topics\/immunisation\/immunisation-throughout-life\/national-immunisation-program-schedule. Accessed 5 Aug 2022."},{"key":"836_CR108","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18773\/austprescr.2019.042","volume":"42","author":"K Sharma","year":"2019","unstructured":"Sharma K, Chiu C, Wood N. Meningococcal vaccines in Australia: a 2019 update. Aust Prescr. 2019;42:131\u20135. https:\/\/doi.org\/10.18773\/austprescr.2019.042.","journal-title":"Aust Prescr"},{"key":"836_CR109","unstructured":"Ministre des Solidarit\u00e9s et de la Sant\u00e9 [France]. Calendrier simplifi\u00e9 des vaccinations 2022 (April 2022). https:\/\/solidarites-sante.gouv.fr\/prevention-en-sante\/preserver-sa-sante\/vaccination\/calendrier-vaccinal. Accessed 5 Aug 2022."},{"key":"836_CR110","doi-asserted-by":"publisher","first-page":"58e1","DOI":"10.1016\/j.anpedi.2022.10.002","volume":"98","author":"FJ \u00c1lvarez Garc\u00eda","year":"2019","unstructured":"\u00c1lvarez Garc\u00eda FJ, Cilleruelo Ortega MJ, \u00c1lvarez Alde\u00e1n J, et al. Calendario de inmunizaciones de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda: recomendaciones 2023. Anal Pediatr. 2023;98:58e1\u2013e10. https:\/\/doi.org\/10.1016\/j.anpedi.2022.10.002.","journal-title":"Anal Pediatr"},{"key":"836_CR111","doi-asserted-by":"publisher","first-page":"2041359","DOI":"10.1080\/21645515.2022.2041359","volume":"18","author":"P Stefanizzi","year":"2022","unstructured":"Stefanizzi P, Bianchi FP, Martinelli A, et al. Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018\u20132020. Hum Vaccin Immunother. 2022;18:2041359. https:\/\/doi.org\/10.1080\/21645515.2022.2041359.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR112","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/pch\/pxx162","volume":"23","author":"JL Robinson","year":"2018","unstructured":"Robinson JL. Update on invasive meningococcal vaccination for Canadian children and youth. Paediatr Child Health. 2018;23:e1\u20134. https:\/\/doi.org\/10.1093\/pch\/pxx162.","journal-title":"Paediatr Child Health"},{"key":"836_CR113","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","volume":"22","author":"B Wang","year":"2022","unstructured":"Wang B, Giles L, Andraweera P, et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect Dis. 2022;22:1011-20. https:\/\/doi.org\/10.1016\/S1473-3099(21)00754-4.","journal-title":"Lancet Infect Dis"},{"key":"836_CR114","unstructured":"Pharmaceutical Management Agency (PHARMAC). Decision to widen access to the meningococcal B vaccine and secure supply of the shingles vaccine, 8 December 2022. https:\/\/pharmac.govt.nz\/news-and-resources\/consultations-and-decisions\/2022-12-08-meningococcal-b-vaccine-notification. Accessed 12 Dec 2022."},{"key":"836_CR115","doi-asserted-by":"publisher","unstructured":"Chicuto LAD, de Moraes C, de Moraes JC, Safadi MAP. A critical analysis of serogroup B meningococcal disease burden in Brazil (2001\u20132015): implications for public health decisions. Hum Vaccin Immunother. 2020;16:1945\u201350. https:\/\/doi.org\/10.1080\/21645515.2019.1700710.","DOI":"10.1080\/21645515.2019.1700710"},{"key":"836_CR116","unstructured":"Public Health England. The Green Book. Chapter 7: Immunisation of individuals with underlying medical conditions. https:\/\/www.gov.uk\/government\/publications\/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7. Accessed 12 Dec 2022."},{"key":"836_CR117","unstructured":"National Advisory Committee on Immunization (NACI). Canadian Immunization Guide. https:\/\/www.canada.ca\/en\/public-health\/services\/canadian-immunization-guide.html. Accessed 5 Aug 2022."},{"key":"836_CR118","unstructured":"Manat\u016b Hauora Ministry of Health. Immunisation Handbook 2020. Chapter 13. Meningococcal disease. https:\/\/www.health.govt.nz\/our-work\/immunisation-handbook-2020\/13-meningococcal-disease. Accessed 12 Dec 2022."},{"key":"836_CR119","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","volume":"382","author":"SN Ladhani","year":"2020","unstructured":"Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382:309\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1901229.","journal-title":"N Engl J Med"},{"key":"836_CR120","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/archdischild-2019-318047","volume":"105","author":"C Isitt","year":"2020","unstructured":"Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020;105:784\u201390. https:\/\/doi.org\/10.1136\/archdischild-2019-318047.","journal-title":"Arch Dis Child"},{"key":"836_CR121","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1001\/jama.2020.20449","volume":"324","author":"FMP Rodrigues","year":"2020","unstructured":"Rodrigues FMP, Marlow R, Simoes MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324:2187\u201394. https:\/\/doi.org\/10.1001\/jama.2020.20449.","journal-title":"JAMA"},{"key":"836_CR122","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/vaccines8030469","volume":"8","author":"C Azzari","year":"2020","unstructured":"Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014\u20132018). Vaccines (Basel). 2020;8:469. https:\/\/doi.org\/10.3390\/vaccines8030469.","journal-title":"Vaccines (Basel)"},{"key":"836_CR123","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2206433","volume":"388","author":"J Castilla","year":"2023","unstructured":"Castilla J, Garcia Cenoz M, Abad R, et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388:427\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2206433.","journal-title":"N Engl J Med"},{"key":"836_CR124","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1093\/cid\/ciaa1636","volume":"73","author":"M McMillan","year":"2021","unstructured":"McMillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73:e233\u20137. https:\/\/doi.org\/10.1093\/cid\/ciaa1636.","journal-title":"Clin Infect Dis"},{"key":"836_CR125","doi-asserted-by":"publisher","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","volume":"76","author":"KJ Bruxvoort","year":"2023","unstructured":"Bruxvoort KJ, Lewnard JA, Chen LH, et al. Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California. Clin Infect Dis. 2023;76:e1341\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac436.","journal-title":"Clin Infect Dis"},{"key":"836_CR126","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1080\/00325481.2020.1766265","volume":"132","author":"J Alderfer","year":"2020","unstructured":"Alderfer J, Isturiz RE, Srivastava A. Lessons from mass vaccination response to meningococcal B outbreaks at US universities. Postgrad Med. 2020;132:614\u201323. https:\/\/doi.org\/10.1080\/00325481.2020.1766265.","journal-title":"Postgrad Med"},{"key":"836_CR127","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1542\/peds.2014-4015","volume":"135","author":"LA McNamara","year":"2015","unstructured":"McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798\u2013804. https:\/\/doi.org\/10.1542\/peds.2014-4015.","journal-title":"Pediatrics"},{"key":"836_CR128","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3201\/eid2503.181574","volume":"25","author":"HM Soeters","year":"2019","unstructured":"Soeters HM, McNamara LA, Blain AE, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013\u20132018. Emerg Infect Dis. 2019;25:434\u201340. https:\/\/doi.org\/10.3201\/eid2503.181574.","journal-title":"Emerg Infect Dis"},{"key":"836_CR129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2051013616681365","volume":"5","author":"A Banzhoff","year":"2017","unstructured":"Banzhoff A. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States. Ther Adv Vaccines. 2017;5:3\u201314. https:\/\/doi.org\/10.1177\/2051013616681365.","journal-title":"Ther Adv Vaccines"},{"key":"836_CR130","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1186\/s12889-020-09487-7","volume":"20","author":"M Pivette","year":"2020","unstructured":"Pivette M, Taha MK, Barret AS, et al. Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017. BMC Public Health. 2020;20:1382. https:\/\/doi.org\/10.1186\/s12889-020-09487-7.","journal-title":"BMC Public Health"},{"key":"836_CR131","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/cid\/cix154","volume":"64","author":"P De Wals","year":"2017","unstructured":"De Wals P, Deceuninck G, Lefebvre B, et al. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64:1263\u20137. https:\/\/doi.org\/10.1093\/cid\/cix154.","journal-title":"Clin Infect Dis"},{"key":"836_CR132","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","volume":"37","author":"G Deceuninck","year":"2019","unstructured":"Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37:4243\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.021.","journal-title":"Vaccine"},{"key":"836_CR133","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/07448481.2017.1285772","volume":"65","author":"TM Fiorito","year":"2017","unstructured":"Fiorito TM, Bornschein S, Mihalakos A, et al. Rapid response to a college outbreak of meningococcal serogroup B disease: Nation\u2019s first widespread use of bivalent rLP2086 vaccine. J Am Coll Health. 2017;65:294\u20136. https:\/\/doi.org\/10.1080\/07448481.2017.1285772.","journal-title":"J Am Coll Health"},{"key":"836_CR134","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/INF.0000000000001742","volume":"37","author":"TM Fiorito","year":"2018","unstructured":"Fiorito TM, Baird GL, Alexander-Scott N, et al. Adverse events following vaccination with bivalent rLP2086 (Trumenba(R)): an observational, longitudinal study during a college outbreak and a systematic review. Pediatr Infect Dis J. 2018;37:e13\u20139. https:\/\/doi.org\/10.1097\/INF.0000000000001742.","journal-title":"Pediatr Infect Dis J"},{"key":"836_CR135","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","volume":"33","author":"KP Perrett","year":"2015","unstructured":"Perrett KP, McVernon J, Richmond PC, et al. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33:5217\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.103.","journal-title":"Vaccine"},{"key":"836_CR136","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya ME, O\u2019Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(11)61713-3.","journal-title":"Lancet"},{"key":"836_CR137","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(14)60842-4.","journal-title":"Lancet"},{"key":"836_CR138","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.vaccine.2015.05.027","volume":"33","author":"J Findlow","year":"2015","unstructured":"Findlow J, Bai X, Findlow H, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33:3322\u201330. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.027.","journal-title":"Vaccine"},{"key":"836_CR139","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3201\/eid2603.190160","volume":"26","author":"JM Langley","year":"2020","unstructured":"Langley JM, Gantt S, Quach C, et al. Randomized trial of 2 schedules of meningococcal B vaccine in adolescents and young adults, Canada. Emerg Infect Dis. 2020;26:454\u201362. https:\/\/doi.org\/10.3201\/eid2603.190160.","journal-title":"Emerg Infect Dis"},{"key":"836_CR140","unstructured":"A Phase 3b, Single-center, open-label study to assess the immunogenicity and safety of Novartis meningococcal B recombinant vaccine when administered at a 0, 2-month schedule in healthy at-risk adults aged 18 to 65 years inclusive. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01911221. Accessed 5 Aug 2022."},{"key":"836_CR141","unstructured":"A Phase 3b study to assess the safety of Novartis meningococcal B recombinant vaccine when administered in healthy at-risk adults. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01478347. Accessed 5 Aug 2022."},{"key":"836_CR142","unstructured":"Safety and blood donations in adults vaccinated with rMenB+OMV NZ. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02305446. Accessed 5 Aug 2022."},{"key":"836_CR143","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","volume":"377","author":"L Ostergaard","year":"2017","unstructured":"Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377:2349\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1614474.","journal-title":"N Engl J Med"},{"key":"836_CR144","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4161\/hv.19983","volume":"8","author":"EA Sheldon","year":"2012","unstructured":"Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012;8:888\u201395. https:\/\/doi.org\/10.4161\/hv.19983.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR145","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","volume":"31","author":"HS Marshall","year":"2013","unstructured":"Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31:1569\u201375. https:\/\/doi.org\/10.1016\/j.vaccine.2013.01.021.","journal-title":"Vaccine"},{"key":"836_CR146","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jinf.2022.09.001","volume":"85","author":"R Bekkat-Berkani","year":"2022","unstructured":"Bekkat-Berkani R, Fragapane E, Preiss S, et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85:481\u201391. https:\/\/doi.org\/10.1016\/j.jinf.2022.09.001.","journal-title":"J Infect"},{"key":"836_CR147","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40121-022-00609-9","volume":"11","author":"GS Marshall","year":"2022","unstructured":"Marshall GS, Fergie J, Presa J, Peyrani P. Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review. Infect Dis Ther. 2022;11:937\u201351. https:\/\/doi.org\/10.1007\/s40121-022-00609-9.","journal-title":"Infect Dis Ther"},{"key":"836_CR148","doi-asserted-by":"publisher","first-page":"e0055321","DOI":"10.1128\/mSphere.00553-21","volume":"6","author":"J Beran","year":"2021","unstructured":"Beran J, Drazan D, Enweonye I, Bhusal C, Toneatto D. Immunogenicity and safety of investigational MenABCWY Vaccine and of 4CMenB and MenACWY vaccines administered concomitantly or alone: a phase 2 randomized study of adolescents and young adults. mSphere. 2021;6:e0055321. https:\/\/doi.org\/10.1128\/mSphere.00553-21.","journal-title":"mSphere."},{"key":"836_CR149","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.vaccine.2021.11.053","volume":"40","author":"D Drazan","year":"2022","unstructured":"Drazan D, Czajka H, Maguire JD, et al. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults. Vaccine. 2022;40:351\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.053.","journal-title":"Vaccine"},{"key":"836_CR150","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/cid\/ciab917","volume":"75","author":"GS Marshall","year":"2022","unstructured":"Marshall GS, Ghaswalla PK, Bengtson LGS, et al. Low meningococcal vaccination rates among patients with newly diagnosed complement component deficiencies in the United States. Clin Infect Dis. 2022;75:155\u20138. https:\/\/doi.org\/10.1093\/cid\/ciab917.","journal-title":"Clin Infect Dis"},{"key":"836_CR151","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.vaccine.2020.11.068","volume":"39","author":"PK Ghaswalla","year":"2021","unstructured":"Ghaswalla PK, Bengtson LGS, Marshall GS, et al. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States. Vaccine. 2021;39:272\u201381. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.068.","journal-title":"Vaccine"},{"key":"836_CR152","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1080\/21645515.2021.1923349","volume":"17","author":"CJ de Oliveira","year":"2021","unstructured":"de Oliveira CJ, Gianacas C, Beard F, et al. Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019. Hum Vaccin Immunother. 2021;17:3692\u2013701. https:\/\/doi.org\/10.1080\/21645515.2021.1923349.","journal-title":"Hum Vaccin Immunother"},{"key":"836_CR153","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14760584.2018.1527690","volume":"17","author":"RK Philip","year":"2018","unstructured":"Philip RK, Attwell K, Breuer T, Di Pasquale A, Lopalco PL. Life-course immunization as a gateway to health. Expert Rev Vaccines. 2018;17:851\u201364. https:\/\/doi.org\/10.1080\/14760584.2018.1527690.","journal-title":"Expert Rev Vaccines"},{"key":"836_CR154","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.vaccine.2021.01.019","volume":"39","author":"P Bonanni","year":"2021","unstructured":"Bonanni P, Villani A, Scotti S, et al. The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: a continuing example of impact on public health policies. Vaccine. 2021;39:1183\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.019.","journal-title":"Vaccine"},{"key":"836_CR155","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41541-021-00354-z","volume":"6","author":"B Laupeze","year":"2021","unstructured":"Laupeze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines. 2021;6:93. https:\/\/doi.org\/10.1038\/s41541-021-00354-z.","journal-title":"NPJ Vaccines"},{"key":"836_CR156","unstructured":"WHO. World Health Organisation. Defeating meningitis by 2030: a global road map. April 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240026407. Accessed 4 Mar 2022."},{"key":"836_CR157","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/trstmh\/trab133","volume":"115","author":"B Greenwood","year":"2021","unstructured":"Greenwood B, Sow S, Preziosi MP. Defeating meningitis by 2030\u2014an ambitious target. Trans R Soc Trop Med Hyg. 2021;115:1099\u2013101. https:\/\/doi.org\/10.1093\/trstmh\/trab133.","journal-title":"Trans R Soc Trop Med Hyg"}],"updated-by":[{"DOI":"10.1007\/s40121-023-00858-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00836-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:25:30Z","timestamp":1697567130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00836-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":157,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00836-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40121-023-00858-2","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-023-00858-2","URL":"https:\/\/doi.org\/10.1007\/s40121-023-00858-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}